Read more about the article Cervical Cancer – New drug combination: Balstilimab Plus Zalifrelimab
Cervical Cancer - New drug combination: Balstilimab Plus Zalifrelimab

Cervical Cancer – New drug combination: Balstilimab Plus Zalifrelimab

Overview Advanced cases of cervical cancer pose a challenge for physicians to treat. Once the cancer cells have spread to other tissues, procedures such as surgery and curative radiation therapy…

Continue ReadingCervical Cancer – New drug combination: Balstilimab Plus Zalifrelimab
Read more about the article Lung cancer – Tiragolumab Plus Atezolizumab Survival
Lung cancer - Tiragolumab Plus Atezolizumab Survival Benefit

Lung cancer – Tiragolumab Plus Atezolizumab Survival

Overview Lung cancer is a very challenging condition to manage, especially when discovered late. The incredibly high incidence of lung cancer – mostly caused by smoking tobacco products – made…

Continue ReadingLung cancer – Tiragolumab Plus Atezolizumab Survival
Read more about the article Cholangiocarcinoma and Gallbladder Cancer – Breakthrough with Imfinzi
Cholangiocarcinoma and Gallbladder Cancer - Breakthrough with Imfinzi

Cholangiocarcinoma and Gallbladder Cancer – Breakthrough with Imfinzi

Overview Ever since their discovery, advanced cases of cholangiocarcinoma and gallbladder cancers have been a big issue for doctors to manage. Since these cancers only present with symptoms when the…

Continue ReadingCholangiocarcinoma and Gallbladder Cancer – Breakthrough with Imfinzi
Read more about the article Melanoma – Alrizomadlin, Fast Track Designation for Advanced Disease
Melanoma – Alrizomadlin, Fast Track Designation for Advanced Disease

Melanoma – Alrizomadlin, Fast Track Designation for Advanced Disease

Overview The FDA has granted a Fast Track Designation to the novel MDM2-p53 inhibitor named “Alrizomadlin” (APG-115) for the treatment of patients with unresectable or metastatic melanoma that is either…

Continue ReadingMelanoma – Alrizomadlin, Fast Track Designation for Advanced Disease